Spirulina for Cholesterol Management

Research suggests that spirulina supplementation may have meaningful hypolipidemic effects, with multiple meta-analyses and systematic reviews of randomized controlled trials consistently reporting reductions in total cholesterol, LDL-C, and triglycerides alongside increases in HDL-C across general adult populations, overweight and obese individuals, and people with type 2 diabetes. Studies indicate these findings are supported by a relatively broad body of evidence spanning in vitro work, animal studies, and human clinical trials, with a 2025 meta-analysis and a 2016 meta-analysis both confirming statistically significant improvements across major lipid markers. A 2022 network meta-analysis comparing ten nutraceuticals found that most, including spirulina, outperformed placebo for LDL reduction, though bergamot and red yeast rice showed larger effects, which provides useful context for understanding spirulina's relative standing among lipid-modifying supplements. Reviewers have consistently noted that while the overall direction of evidence is supportive, methodological limitations in individual trials — such as small sample sizes and variability in study design — mean the findings should be interpreted with some caution, and further large-scale, well-controlled trials would strengthen confidence in these results.